Analgesic nephropathy overview: Difference between revisions
Jump to navigation
Jump to search
| (23 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{Analgesic nephropathy}} | {{Analgesic nephropathy}} | ||
{{CMG}} {{AE}} {{SHA}} | {{CMG}} {{AE}} {{SHA}} | ||
==Overview== | ==Overview== | ||
Analgesic nephropathy is a disorder caused by long-term use of analgesic drugs, mainly [[phenacetin]] and combinations containing [[phenacetin]]. This resulted in the withdrawal of [[phenacetin]] from most markets around the world since over 30 years ago, which has led to the disappearance of classic analgesic nephropathy caused by [[phenacetin]]. The main findings in analgesic nephropathy are [[renal papillary necrosis]] and chronic [[interstitial nephritis]]. The kidney injury may progress to [[End stage renal disease|end stage renal disease (ESRD)]]. Although non-[[phenacetin]] analgesics (such as [[Non-steroidal anti-inflammatory drug|NSAIDs]], [[aspirin]] and [[acetaminophen]]) or their combinations have been reported in some studies as causes to analgesic nephropathy, but there is insufficient evidence that suggests these drugs cause analgesic nephropathy. | |||
==Historical Perspective== | ==Historical Perspective== | ||
In 1953, the association between [[analgesic]] drugs and [[Chronic renal failure|chronic renal disease]] was first reported in German.<ref name="pmid13137299">{{cite journal |author=Spühler O, Zollinger HU |title=Die chronisch-interstitielle Nephritis. |language=German |journal=Z Klin Med |volume=151 |issue=1 |pages=1–50 |year=1953 |pmid=13137299 |doi= |url=}}</ref> In 1977, [[phenacetin]] | In 1953, the association between [[analgesic]] drugs and [[Chronic renal failure|chronic renal disease]] was first reported in German.<ref name="pmid13137299">{{cite journal |author=Spühler O, Zollinger HU |title=Die chronisch-interstitielle Nephritis. |language=German |journal=Z Klin Med |volume=151 |issue=1 |pages=1–50 |year=1953 |pmid=13137299 |doi= |url=}}</ref> In 1977, Australia was first to legally ban [[phenacetin]].<ref name="pmid11181803">{{cite journal| author=Michielsen P, de Schepper P| title=Trends of analgesic nephropathy in two high-endemic regions with different legislation. | journal=J Am Soc Nephrol | year= 2001 | volume= 12 | issue= 3 | pages= 550-6 | pmid=11181803 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11181803 }} </ref> In 1983, [[phenacetin]] was withdrawn from the US markets.<ref name="pmid10557618">{{cite journal| author=| title=List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule. | journal=Fed Regist | year= 1999 | volume= 64 | issue= 44 | pages= 10944-7 | pmid=10557618 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10557618 }} </ref> | ||
== Pathopysiology == | == Pathopysiology == | ||
The pathogenesis of analgesic nephropathy caused by [[phenacetin]] may be due to several reasons. Toxic metabolites of [[phenacetin]] cause capillary sclerosis in the [[renal medulla]], which results in [[renal papillary necrosis]], tubulointerstitial nephropathy and cortical [[atrophy]].<ref name="pmid6641031">{{cite journal| author=Mihatsch MJ, Hofer HO, Gudat F, Knüsli C, Torhorst J, Zollinger HU| title=Capillary sclerosis of the urinary tract and analgesic nephropathy. | journal=Clin Nephrol | year= 1983 | volume= 20 | issue= 6 | pages= 285-301 | pmid=6641031 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6641031 }} </ref><ref name="pmid16891638">{{cite journal| author=Mihatsch MJ, Khanlari B, Brunner FP| title=Obituary to analgesic nephropathy--an autopsy study. | journal=Nephrol Dial Transplant | year= 2006 | volume= 21 | issue= 11 | pages= 3139-45 | pmid=16891638 | doi=10.1093/ndt/gfl390 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16891638 }} </ref> [[Renal ischemia]] and [[renal papillary necrosis]] may be result from the [[methemoglobinemia]] caused by [[phenacetin]].<ref name="pmid4827469">{{cite journal| author=Gault MH, Shahidi NT, Barber VE| title=Methemoglobin formation in analgesic nephropathy. | journal=Clin Pharmacol Ther | year= 1974 | volume= 15 | issue= 5 | pages= 521-7 | pmid=4827469 | doi=10.1002/cpt1974155521 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4827469 }} </ref> Additionally, It has been reported that the concentration of [[Salicylic acid|phenacetin]] is higher at the papillary which is suggestive of direct damage to the renal papillary cells.<ref name="pmid5813230">{{cite journal| author=Bluemle LW, Goldberg M| title=Renal accumulation of salicylate and phenacetin: possible mechanisms in the nephropathy of analgesic abuse. | journal=J Clin Invest | year= 1969 | volume= 47 | issue= 11 | pages= 2507-14 | pmid=5813230 | doi=10.1172/JCI105932 | pmc=297415 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5813230 }} </ref> Although non-[[phenacetin]] analgesics (such as [[Non-steroidal anti-inflammatory drug|NSAIDs]], [[aspirin]] and [[acetaminophen]]) or their combinations have been reported in some studies as causes to analgesic nephropathy, but there is insufficient evidence that suggests these drugs cause analgesic nephropathy.<ref name="pmid11115060">{{cite journal| author=Feinstein AR, Heinemann LA, Curhan GC, Delzell E, Deschepper PJ, Fox JM | display-authors=etal| title=Relationship between nonphenacetin combined analgesics and nephropathy: a review. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy. | journal=Kidney Int | year= 2000 | volume= 58 | issue= 6 | pages= 2259-64 | pmid=11115060 | doi=10.1046/j.1523-1755.2000.00410.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11115060 }} </ref><ref name="pmid9556702">{{cite journal| author=Delzell E, Shapiro S| title=A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. | journal=Medicine (Baltimore) | year= 1998 | volume= 77 | issue= 2 | pages= 102-21 | pmid=9556702 | doi=10.1097/00005792-199803000-00003 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9556702 }} </ref> | |||
== Causes == | == Causes == | ||
There is a strong association between [[phenacetin]] and analgesic nephropathy which has led to the disappearing of classic analgesic nephropathy after the removal of [[phenacetin]] from the markets over 30 years ago.<ref name="pmid27900067">{{cite journal| author=Yaxley J| title=Common Analgesic Agents and Their Roles in Analgesic Nephropathy: A Commentary on the Evidence. | journal=Korean J Fam Med | year= 2016 | volume= 37 | issue= 6 | pages= 310-316 | pmid=27900067 | doi=10.4082/kjfm.2016.37.6.310 | pmc=5122661 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27900067 }} </ref><ref name="pmid16891638">{{cite journal| author=Mihatsch MJ, Khanlari B, Brunner FP| title=Obituary to analgesic nephropathy--an autopsy study. | journal=Nephrol Dial Transplant | year= 2006 | volume= 21 | issue= 11 | pages= 3139-45 | pmid=16891638 | doi=10.1093/ndt/gfl390 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16891638 }} </ref> Although non-phenacetin [[Analgesic|analgesics]] (such as [[Non-steroidal anti-inflammatory drug|NSAIDs]], [[aspirin]] and [[acetaminophen]]) or their combinations have been reported in some studies as causes to analgesic nephropathy, but there is insufficient evidence that suggests these drugs cause analgesic nephropathy.<ref name="pmid11115060">{{cite journal| author=Feinstein AR, Heinemann LA, Curhan GC, Delzell E, Deschepper PJ, Fox JM | display-authors=etal| title=Relationship between nonphenacetin combined analgesics and nephropathy: a review. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy. | journal=Kidney Int | year= 2000 | volume= 58 | issue= 6 | pages= 2259-64 | pmid=11115060 | doi=10.1046/j.1523-1755.2000.00410.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11115060 }} </ref><ref name="pmid9556702">{{cite journal| author=Delzell E, Shapiro S| title=A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. | journal=Medicine (Baltimore) | year= 1998 | volume= 77 | issue= 2 | pages= 102-21 | pmid=9556702 | doi=10.1097/00005792-199803000-00003 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9556702 }} </ref> | |||
== Differentiating Analgesic nephropathy from other Diseases == | == Differentiating Analgesic nephropathy from other Diseases == | ||
Analgesic nephropathy should be differentiated with other disorders that cause [[renal papillary necrosis]], such as: [[diabetic nephropathy]], renal crisis in [[Sickle-cell disease|sickle cell disease]], [[pyelonephritis]], obstructive uropathy, [[renal tuberculosis]], alcohol-induced nephropathy, systemic [[vasculitis]] and [[renal vein thrombosis]].<ref name="pmid31082145">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume= | issue= | pages= | pmid=31082145 | doi= | pmc= | url= }} </ref><ref name="pmid26184064">{{cite journal| author=Chalhoub NE, Riley K, Siddiqui N, Assaly R, Shahrour K, Booth R | display-authors=etal| title=Renal Papillary Necrosis Due to Invasive Candida Infection in a Morbidly Obese Patient. | journal=J Urol | year= 2015 | volume= 194 | issue= 4 | pages= 1107-8 | pmid=26184064 | doi=10.1016/j.juro.2015.07.036 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26184064 }} </ref><ref name="pmid29984778">{{cite journal| author=Kawaguchi Y, Mori H, Izumi Y, Ito M| title=Renal Papillary Necrosis with Diabetes and Urinary Tract Infection. | journal=Intern Med | year= 2018 | volume= 57 | issue= 22 | pages= 3343 | pmid=29984778 | doi=10.2169/internalmedicine.0858-18 | pmc=6288002 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29984778 }} </ref> | |||
== Risk Factors == | == Risk Factors == | ||
[[Risk factor|Risk factors]] for renal insufficiency from [[Non-steroidal anti-inflammatory drug|NSAIDs]] include: history of [[Kidney|renal]] disorder, older age, [[Congestive heart failure|congestive heart failure (CHF)]], [[cirrhosis]] with [[ascites]], [[nephrotic syndrome]], history of [[Bleeding|hemorrhage]] or [[surgery]], [[Nausea and vomiting|vomiting]] and [[diarrhea]].<ref name="pmid9601134">{{cite journal| author=Henrich WL| title=Analgesic nephropathy. | journal=Trans Am Clin Climatol Assoc | year= 1998 | volume= 109 | issue= | pages= 147-58; discussion 158-9 | pmid=9601134 | doi= | pmc=2194329 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9601134 }} </ref> | |||
== Screening == | == Screening == | ||
| Line 34: | Line 27: | ||
== Natural History, Complications and Prognosis == | == Natural History, Complications and Prognosis == | ||
The prognosis of analgesic nephropathy depends on the scarring and damage to the renal tissue. Most patients in early stages recover to normal [[renal function]] after stopping the [[analgesic]] drug, however some may progress to [[End stage renal disease|end stage renal disease (ESRD)]]. Complications of analgesic nephropathy include: [[Urinary tract infection|urinary tract infections]], varying degrees of [[Renal insufficiency|renal failure]] and [[End stage renal disease| | The prognosis of analgesic nephropathy depends on the scarring and damage to the renal tissue.<ref name="pmid31082145" /> Most patients in early stages recover to normal [[renal function]] after stopping the [[analgesic]] drug, however some may progress to [[End stage renal disease|end stage renal disease (ESRD)]].<ref name="pmid31082145" /> Complications of analgesic nephropathy include: [[Urinary tract infection|urinary tract infections]], varying degrees of [[Renal insufficiency|renal failure]] and [[End stage renal disease|end stage renal disease (ESRD)]].<ref name="pmid7002190">{{cite journal| author=Nanra RS| title=Clinical and pathological aspects of analgesic nephropathy. | journal=Br J Clin Pharmacol | year= 1980 | volume= 10 Suppl 2 | issue= | pages= 359S-368S | pmid=7002190 | doi=10.1111/j.1365-2125.1980.tb01824.x | pmc=1430193 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7002190 }} </ref><ref name="pmid362034">{{cite journal| author=Nanra RS, Stuart-Taylor J, de Leon AH, White KH| title=Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. | journal=Kidney Int | year= 1978 | volume= 13 | issue= 1 | pages= 79-92 | pmid=362034 | doi=10.1038/ki.1978.11 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=362034 }} </ref><ref name="pmid31082145">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume= | issue= | pages= | pmid=31082145 | doi= | pmc= | url= }} </ref> | ||
== Epidemiology and Demographics == | == Epidemiology and Demographics == | ||
There is insufficient evidence about the [[incidence]], [[prevalence]] and racial predilection of analgesic nephropathy. Most patients with analgesic nephropathy have been reported to be middle age or older with a history of chronic pain.<ref name="pmid28582877">{{cite journal| author=Yaxley J| title=Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence. | journal=Int J Risk Saf Med | year= 2016 | volume= 28 | issue= 4 | pages= 189-196 | pmid=28582877 | doi=10.3233/JRS-170735 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28582877 }} </ref> | There is insufficient evidence about the [[incidence]], [[prevalence]] and racial predilection of analgesic nephropathy. However, the classic analgesic nephropathy is disappearing after the removal of [[phenacetin]] from the markets over 30 years ago.<ref name="pmid16891638">{{cite journal| author=Mihatsch MJ, Khanlari B, Brunner FP| title=Obituary to analgesic nephropathy--an autopsy study. | journal=Nephrol Dial Transplant | year= 2006 | volume= 21 | issue= 11 | pages= 3139-45 | pmid=16891638 | doi=10.1093/ndt/gfl390 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16891638 }} </ref> Most patients with analgesic nephropathy have been reported to be middle age or older with a history of chronic pain.<ref name="pmid28582877">{{cite journal| author=Yaxley J| title=Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence. | journal=Int J Risk Saf Med | year= 2016 | volume= 28 | issue= 4 | pages= 189-196 | pmid=28582877 | doi=10.3233/JRS-170735 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28582877 }} </ref> Studies suggest that analgesic nephropathy is more conman in females than males.<ref name="pmid713269">{{cite journal| author=Gault MH, Wilson DR| title=Analgesic nephropathy in Canada: clinical syndrome, management, and outcome. | journal=Kidney Int | year= 1978 | volume= 13 | issue= 1 | pages= 58-63 | pmid=713269 | doi=10.1038/ki.1978.8 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=713269 }} </ref> | ||
== Diagnosis == | == Diagnosis == | ||
| Line 64: | Line 57: | ||
=== CT Scan === | === CT Scan === | ||
[[Computed tomography|CT scan]] without [[Contrast medium|contrast]] of the abdomen is usually preferred for diagnosing analgesic nephropathy, the findings include: decrease in [[Kidney|renal]] size, | [[Computed tomography|CT scan]] without [[Contrast medium|contrast]] of the abdomen is usually preferred for diagnosing analgesic nephropathy, the findings include: decrease in [[Kidney|renal]] size, irregular contours and papillary [[Calcification|calcifications]].<ref name="pmid9459649">{{cite journal |author=de Broe ME, Elseviers MM |title=Analgesic nephropathy |journal=N. Engl. J. Med. |volume=338 |issue=7 |pages=446–52 |year=1998 |month=February |pmid=9459649 |doi= |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=9459649&promo=ONFLNS19}}</ref> | ||
=== MRI === | === MRI === | ||
| Line 78: | Line 71: | ||
=== Medical therapy === | === Medical therapy === | ||
Medical treatment of analgesic nephropathy may include:<ref name="pmid7002190">{{cite journal| author=Nanra RS| title=Clinical and pathological aspects of analgesic nephropathy. | journal=Br J Clin Pharmacol | year= 1980 | volume= 10 Suppl 2 | issue= | pages= 359S-368S | pmid=7002190 | doi=10.1111/j.1365-2125.1980.tb01824.x | pmc=1430193 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7002190 }} </ref><ref name="pmid31082145">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume= | issue= | pages= | pmid=31082145 | doi= | pmc= | url= }} </ref> | Medical treatment of analgesic nephropathy may include: discontinuation of [[Analgesic|analgesics]], adequate hydration with normal [[Saline (medicine)|saline]] and treatment of [[Infection|infections]] with [[Antibiotic|antibiotics]].<ref name="pmid7002190">{{cite journal| author=Nanra RS| title=Clinical and pathological aspects of analgesic nephropathy. | journal=Br J Clin Pharmacol | year= 1980 | volume= 10 Suppl 2 | issue= | pages= 359S-368S | pmid=7002190 | doi=10.1111/j.1365-2125.1980.tb01824.x | pmc=1430193 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7002190 }} </ref><ref name="pmid31082145">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume= | issue= | pages= | pmid=31082145 | doi= | pmc= | url= }} </ref> | ||
=== Interventions === | === Interventions === | ||
Patients with analgesic nephropathy that present with [[Acute kidney injury|acute renal failure]] or progression to [[End stage renal disease|end stage renal disease (ESRD)]] may require [[renal replacement therapy]] with [[dialysis]].<ref name="pmid4638849">{{cite journal |author=Linton AL |title=Renal disease due to analgesics. I. Recognition of the problem of analgesic nephropathy |journal=Can Med Assoc J |volume=107 |issue=8 |pages=749–51 |year=1972 |month=October |pmid=4638849 |pmc=1941002 |doi= |url=}}</ref><ref name="pmid7002190">{{cite journal| author=Nanra RS| title=Clinical and pathological aspects of analgesic nephropathy. | journal=Br J Clin Pharmacol | year= 1980 | volume= 10 Suppl 2 | issue= | pages= 359S-368S | pmid=7002190 | doi=10.1111/j.1365-2125.1980.tb01824.x | pmc=1430193 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7002190 }} </ref> | |||
=== Surgery === | === Surgery === | ||
Patients with analgesic nephropathy that progress to [[End stage renal disease|end stage renal disease (ESRD)]] may require [[renal replacement therapy]] with [[Kidney transplantation|renal transplantation]].<ref name="pmid4638849" /> | |||
=== Prevention === | === Prevention === | ||
| Line 88: | Line 83: | ||
=== Cost-Effectiveness of Therapy === | === Cost-Effectiveness of Therapy === | ||
There is insufficient evidence about the cost-effectiveness of therapy in analgesic nephropathy. | |||
=== Future or Investigational Therapies === | === Future or Investigational Therapies === | ||
No further or investigational therapies have been suggested in analgesic nephropathy. | |||
==References== | ==References== | ||
Latest revision as of 06:28, 8 July 2020
|
Analgesic nephropathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Analgesic nephropathy overview On the Web |
|
American Roentgen Ray Society Images of Analgesic nephropathy overview |
|
Risk calculators and risk factors for Analgesic nephropathy overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
Analgesic nephropathy is a disorder caused by long-term use of analgesic drugs, mainly phenacetin and combinations containing phenacetin. This resulted in the withdrawal of phenacetin from most markets around the world since over 30 years ago, which has led to the disappearance of classic analgesic nephropathy caused by phenacetin. The main findings in analgesic nephropathy are renal papillary necrosis and chronic interstitial nephritis. The kidney injury may progress to end stage renal disease (ESRD). Although non-phenacetin analgesics (such as NSAIDs, aspirin and acetaminophen) or their combinations have been reported in some studies as causes to analgesic nephropathy, but there is insufficient evidence that suggests these drugs cause analgesic nephropathy.
Historical Perspective
In 1953, the association between analgesic drugs and chronic renal disease was first reported in German.[1] In 1977, Australia was first to legally ban phenacetin.[2] In 1983, phenacetin was withdrawn from the US markets.[3]
Pathopysiology
The pathogenesis of analgesic nephropathy caused by phenacetin may be due to several reasons. Toxic metabolites of phenacetin cause capillary sclerosis in the renal medulla, which results in renal papillary necrosis, tubulointerstitial nephropathy and cortical atrophy.[4][5] Renal ischemia and renal papillary necrosis may be result from the methemoglobinemia caused by phenacetin.[6] Additionally, It has been reported that the concentration of phenacetin is higher at the papillary which is suggestive of direct damage to the renal papillary cells.[7] Although non-phenacetin analgesics (such as NSAIDs, aspirin and acetaminophen) or their combinations have been reported in some studies as causes to analgesic nephropathy, but there is insufficient evidence that suggests these drugs cause analgesic nephropathy.[8][9]
Causes
There is a strong association between phenacetin and analgesic nephropathy which has led to the disappearing of classic analgesic nephropathy after the removal of phenacetin from the markets over 30 years ago.[10][5] Although non-phenacetin analgesics (such as NSAIDs, aspirin and acetaminophen) or their combinations have been reported in some studies as causes to analgesic nephropathy, but there is insufficient evidence that suggests these drugs cause analgesic nephropathy.[8][9]
Differentiating Analgesic nephropathy from other Diseases
Analgesic nephropathy should be differentiated with other disorders that cause renal papillary necrosis, such as: diabetic nephropathy, renal crisis in sickle cell disease, pyelonephritis, obstructive uropathy, renal tuberculosis, alcohol-induced nephropathy, systemic vasculitis and renal vein thrombosis.[11][12][13]
Risk Factors
Risk factors for renal insufficiency from NSAIDs include: history of renal disorder, older age, congestive heart failure (CHF), cirrhosis with ascites, nephrotic syndrome, history of hemorrhage or surgery, vomiting and diarrhea.[14]
Screening
There is insufficient evidence to recommend routine screening for analgesic nephropathy.
Natural History, Complications and Prognosis
The prognosis of analgesic nephropathy depends on the scarring and damage to the renal tissue.[11] Most patients in early stages recover to normal renal function after stopping the analgesic drug, however some may progress to end stage renal disease (ESRD).[11] Complications of analgesic nephropathy include: urinary tract infections, varying degrees of renal failure and end stage renal disease (ESRD).[15][16][11]
Epidemiology and Demographics
There is insufficient evidence about the incidence, prevalence and racial predilection of analgesic nephropathy. However, the classic analgesic nephropathy is disappearing after the removal of phenacetin from the markets over 30 years ago.[5] Most patients with analgesic nephropathy have been reported to be middle age or older with a history of chronic pain.[17] Studies suggest that analgesic nephropathy is more conman in females than males.[18]
Diagnosis
Diagnostic Study of Choice
Renal biopsy is the diagnostic study of choice, however, since it is an invasive procedure, CT scan without contrast of the abdomen is usually preferred.[19][20]
History and Symptoms
Common findings in patients with analgesic nephropathy include: headache, upper gastrointestinal disease (such as peptic ulcer), anemia, urinary tract infections, pyuria and hypertension.[15][16]
Physical Examination
In physical examination of patients with analgesic nephropathy checking for the followings should be considered: headache, upper gastrointestinal disease (such as peptic ulcer), anemia, urinary tract infections, and hypertension.[15][16]
Laboratory Findings
The laboratory tests and findings in analgesic nephropathy may include: urinary examination (sterile pyuria, hematuria, proteinuria and bacteriuria) and blood tests (anemia and renal failure).[15][16][11]
Electrocardiogram
There are no ECG findings associated with analgesic nephropathy.
X-ray
A pyelogram is not helpful in the diagnosis of analgesic nephropathy and may worsen the renal injury due to contrast utilization.[19]
Ultrasound
There are no ultrasound findings associated with analgesic nephropathy. However, ultrasound of the abdomen, kidneys and the urinary bladder could be helpful in ruling out other causes of nephropathy (obstruction or infection).[11]
CT Scan
CT scan without contrast of the abdomen is usually preferred for diagnosing analgesic nephropathy, the findings include: decrease in renal size, irregular contours and papillary calcifications.[20]
MRI
There is insufficient evidence suggesting MRI findings associated with analgesic nephropathy.
Other Imaging Findings
There are no other imaging findings associated with analgesic nephropathy.
Other Diagnostic studies
There are no other diagnostic studies associated with analgesic nephropathy.
Treatment
Medical therapy
Medical treatment of analgesic nephropathy may include: discontinuation of analgesics, adequate hydration with normal saline and treatment of infections with antibiotics.[15][11]
Interventions
Patients with analgesic nephropathy that present with acute renal failure or progression to end stage renal disease (ESRD) may require renal replacement therapy with dialysis.[21][15]
Surgery
Patients with analgesic nephropathy that progress to end stage renal disease (ESRD) may require renal replacement therapy with renal transplantation.[21]
Prevention
It has been suggested that in clinical practice, non-opioid analgesics, when possible, should be avoided for long-term use due to their nephrotoxicity.[17]
Cost-Effectiveness of Therapy
There is insufficient evidence about the cost-effectiveness of therapy in analgesic nephropathy.
Future or Investigational Therapies
No further or investigational therapies have been suggested in analgesic nephropathy.
References
- ↑ Spühler O, Zollinger HU (1953). "Die chronisch-interstitielle Nephritis". Z Klin Med (in German). 151 (1): 1–50. PMID 13137299.
- ↑ Michielsen P, de Schepper P (2001). "Trends of analgesic nephropathy in two high-endemic regions with different legislation". J Am Soc Nephrol. 12 (3): 550–6. PMID 11181803.
- ↑ "List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule". Fed Regist. 64 (44): 10944–7. 1999. PMID 10557618.
- ↑ Mihatsch MJ, Hofer HO, Gudat F, Knüsli C, Torhorst J, Zollinger HU (1983). "Capillary sclerosis of the urinary tract and analgesic nephropathy". Clin Nephrol. 20 (6): 285–301. PMID 6641031.
- ↑ 5.0 5.1 5.2 Mihatsch MJ, Khanlari B, Brunner FP (2006). "Obituary to analgesic nephropathy--an autopsy study". Nephrol Dial Transplant. 21 (11): 3139–45. doi:10.1093/ndt/gfl390. PMID 16891638.
- ↑ Gault MH, Shahidi NT, Barber VE (1974). "Methemoglobin formation in analgesic nephropathy". Clin Pharmacol Ther. 15 (5): 521–7. doi:10.1002/cpt1974155521. PMID 4827469.
- ↑ Bluemle LW, Goldberg M (1969). "Renal accumulation of salicylate and phenacetin: possible mechanisms in the nephropathy of analgesic abuse". J Clin Invest. 47 (11): 2507–14. doi:10.1172/JCI105932. PMC 297415. PMID 5813230.
- ↑ 8.0 8.1 Feinstein AR, Heinemann LA, Curhan GC, Delzell E, Deschepper PJ, Fox JM; et al. (2000). "Relationship between nonphenacetin combined analgesics and nephropathy: a review. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy". Kidney Int. 58 (6): 2259–64. doi:10.1046/j.1523-1755.2000.00410.x. PMID 11115060.
- ↑ 9.0 9.1 Delzell E, Shapiro S (1998). "A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease". Medicine (Baltimore). 77 (2): 102–21. doi:10.1097/00005792-199803000-00003. PMID 9556702.
- ↑ Yaxley J (2016). "Common Analgesic Agents and Their Roles in Analgesic Nephropathy: A Commentary on the Evidence". Korean J Fam Med. 37 (6): 310–316. doi:10.4082/kjfm.2016.37.6.310. PMC 5122661. PMID 27900067.
- ↑ 11.0 11.1 11.2 11.3 11.4 11.5 11.6 "StatPearls". 2020. PMID 31082145.
- ↑ Chalhoub NE, Riley K, Siddiqui N, Assaly R, Shahrour K, Booth R; et al. (2015). "Renal Papillary Necrosis Due to Invasive Candida Infection in a Morbidly Obese Patient". J Urol. 194 (4): 1107–8. doi:10.1016/j.juro.2015.07.036. PMID 26184064.
- ↑ Kawaguchi Y, Mori H, Izumi Y, Ito M (2018). "Renal Papillary Necrosis with Diabetes and Urinary Tract Infection". Intern Med. 57 (22): 3343. doi:10.2169/internalmedicine.0858-18. PMC 6288002. PMID 29984778.
- ↑ Henrich WL (1998). "Analgesic nephropathy". Trans Am Clin Climatol Assoc. 109: 147–58, discussion 158-9. PMC 2194329. PMID 9601134.
- ↑ 15.0 15.1 15.2 15.3 15.4 15.5 Nanra RS (1980). "Clinical and pathological aspects of analgesic nephropathy". Br J Clin Pharmacol. 10 Suppl 2: 359S–368S. doi:10.1111/j.1365-2125.1980.tb01824.x. PMC 1430193. PMID 7002190.
- ↑ 16.0 16.1 16.2 16.3 Nanra RS, Stuart-Taylor J, de Leon AH, White KH (1978). "Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia". Kidney Int. 13 (1): 79–92. doi:10.1038/ki.1978.11. PMID 362034.
- ↑ 17.0 17.1 Yaxley J (2016). "Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence". Int J Risk Saf Med. 28 (4): 189–196. doi:10.3233/JRS-170735. PMID 28582877.
- ↑ Gault MH, Wilson DR (1978). "Analgesic nephropathy in Canada: clinical syndrome, management, and outcome". Kidney Int. 13 (1): 58–63. doi:10.1038/ki.1978.8. PMID 713269.
- ↑ 19.0 19.1 "Analgesic Nephropathy - StatPearls - NCBI Bookshelf".
- ↑ 20.0 20.1 de Broe ME, Elseviers MM (1998). "Analgesic nephropathy". N. Engl. J. Med. 338 (7): 446–52. PMID 9459649. Unknown parameter
|month=ignored (help) - ↑ 21.0 21.1 Linton AL (1972). "Renal disease due to analgesics. I. Recognition of the problem of analgesic nephropathy". Can Med Assoc J. 107 (8): 749–51. PMC 1941002. PMID 4638849. Unknown parameter
|month=ignored (help)